Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone

NCT06331104 | Completed

• 1 other identifier: ChangyeZou
• Study Type: observational
• Target: 145
• Locations: 1 country
• Sites: 1

Brief Summary

Based on network pharmacology analysis, this study aims to explore the potential therapeutic targets and molecular mechanisms of puerarin on giant cell tumor of bone (GCTB) genes.

Conditions

Giant Cell Tumors

Keywords

Giant Cell Tumors; Puerarin; Treatment; Traditional Chinese medicine; Network Pharmacology

Outcome Measures

Primary Outcomes (2)

• P27 expression levels

  12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).

  2023-05-18 - 2023-08-31

• ESR1 expression levels

  12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).

  2023-05-18 - 2023-08-31

Study Arms (2)

P27 expression groups

12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).

Genetic: gene expression levels

ESR1 expression groups

12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).

Genetic: gene expression levels

Interventions

gene expression levels GENETIC

12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).

ESR1 expression groups; P27 expression groups

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

1st hospital of SYSU provides diagnosis and treatment that meets the inclusion criteria.

You may qualify if:

• Diagnosed as a patient with giant cell tumor of bone;
• Performing surgical treatment in 1st hospital of SYSU;
• Having complete clinical registration information;
• Preserve surgical or puncture specimens;

You may not qualify if:

• Non bone giant cell tumor patients;
• No surgical treatment was performed;
• Incomplete clinical information registration;
• No preserved surgical or puncture specimens.

Sponsors & Collaborators

• Changye Zou: lead

Study Sites (1)

Churong Yan

Guangzhou, Guangdong, 518010, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Immunohistochemistry (IHC) and immunofluorescence staining were performed on the GCTB tissues of 145 patients (2 normal tissues, 51 recurrent, and 92 primary) from the First Affiliated Hospital of Sun Yat sen University to verify the differential expression and distribution of P27 and ESR1 in recurrent and primary lesions of giant cell tumor of bone patients. One patient's tissue was used for transcriptome sequencing to analyze changes in gene expression levels before and after routine treatment.

MeSH Terms

Conditions

Giant Cell Tumors

Condition Hierarchy (Ancestors)

Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Study Officials

• Changye Zou, MD

  First Affiliated Hospital, Sun Yat-Sen University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Department of Orthopedic Oncology, The First Affiliated Hospital of Sun Yat-sen University

Study Record Dates

• First Submitted: March 19, 2024
• First Posted: March 26, 2024
• Study Start: June 14, 2012
• Primary Completion: August 31, 2023
• Study Completion: August 31, 2023
• Last Updated: April 2, 2024

Record last verified: 2024-03

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP
• Time Frame: SCI online. The datasets are available from the corresponding author on reasonable request.
• Access Criteria: The datasets are available from the corresponding author (zouchy@mail.sysu.edu.cn) on reasonable request after SCI online.

Locations

CN (1)